




- (51) **International Patent Classification:**
C07D 471/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/437 (2006.01)
- (21) **International Application Number:**
PCT/GB2015/051312
- (22) **International Filing Date:**
5 May 2015 (05.05.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/990,232 8 May 2014 (08.05.2014) US
- (71) **Applicant (for all designated States except MG):** **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).
- (71) **Applicant (for MG only):** **ASTRAZENECA UK LIMITED** [GB/GB]; 2 Kingdom Street, London, Greater London W2 6BD (GB).
- (72) **Inventors:** **BARLAAM, Bernard Christophe**; AstraZeneca R&D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **PIKE, Kurt Gordon**; AstraZeneca R&D Cambridge, Darwin Building, Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0FZ (GB).
- (74) **Agents:** **ASTRAZENECA INTELLECTUAL PROPERTY** et al.; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (SE).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report (Art. 21(3))

(54) **Title:** IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER



(57) **Abstract:** The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where Q, R¹, R², R³, R⁴ and R⁵ have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating ATM kinase mediated disease, including cancer, using such compounds and salts.

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE

(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

ASTRAZENECA INTELLECTUAL PROPERTY
AstraZeneca R&D Alderley
Alderley Park
Macclesfield
Cheshire SK10 4TG
SUÈDE

Date of mailing (day/month/year) 26 July 2016 (26.07.2016)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference 200222-WOPCT	
International application No. PCT/GB2015/051312	
	International filing date (day/month/year) 05 May 2015 (05.05.2015)

1. The following indications appeared on record concerning:

☐ the applicant☒ the inventor☐ the agent☐ the common representative

Name and Address BARLAAM, Bernard Christophe AstraZeneca R&D Alderley Alderley Park Macclesfield Cheshire SK10 4TG United Kingdom	State of Nationality	State of Residence
	Telephone No.	
	Facsimile No.	
	E-mail address	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person☐ the name☒ the address☐ the nationality☐ the residence

Name and Address BARLAAM, Bernard Christophe AstraZeneca Darwin Building Cambridge Science Park Milton Road Cambridge, CB4 0WG United Kingdom	State of Nationality	State of Residence
	Telephone No.	
	Facsimile No.	
	E-mail address ☐ Notifications by e-mail authorized	

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☐ the receiving Office☒ the International Searching Authority☐ the Authority(ies) specified for supplementary search

☐ the International Preliminary Examining Authority☒ the designated Offices concerned☐ the elected Offices concerned☐ other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. +41 22 338 89 95	Authorized officer Safi Horiya e-mail pt04.pct@wipo.int Telephone No. +41 22 338 74 04
---	---

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE

(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

ASTRAZENECA INTELLECTUAL PROPERTY
AstraZeneca R&D Alderley
Alderley Park
Macclesfield
Cheshire SK10 4TG
SUÈDE

Date of mailing (day/month/year) 26 July 2016 (26.07.2016)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference 200222-WOPCT	
International application No. PCT/GB2015/051312	International filing date (day/month/year) 05 May 2015 (05.05.2015)

1. The following indications appeared on record concerning:

☐ the applicant

☒ the inventor

☐ the agent

☐ the common representative

Name and Address PIKE, Kurt Gordon AstraZeneca R&D Cambridge Darwin Building Cambridge Science Park Milton Road Cambridge Cambridgeshire CB4 0FZ United Kingdom	State of Nationality	State of Residence
	Telephone No.	
	Facsimile No.	
	E-mail address	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person

☐ the name

☒ the address

☐ the nationality

☐ the residence

Name and Address PIKE, Kurt Gordon AstraZeneca, Darwin Building, Cambridge Science Park, Milton Road, Cambridge CB4 0WG United Kingdom	State of Nationality	State of Residence
	Telephone No.	
	Facsimile No.	
	E-mail address ☐ Notifications by e-mail authorized	

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☐ the receiving Office

☒ the International Searching Authority

☐ the Authority(ies) specified for supplementary search

☐ the International Preliminary Examining Authority

☒ the designated Offices concerned

☐ the elected Offices concerned

☐ other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. +41 22 338 89 95	Authorized officer Safi Horiya e-mail pt04.pct@wipo.int Telephone No. +41 22 338 74 04
---	---

CORRECTED VERSION

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE

(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

ASTRAZENECA INTELLECTUAL PROPERTY
AstraZeneca R&D Alderley
Alderley Park
Macclesfield
Cheshire SK10 4TG
SUÈDE

Date of mailing (day/month/year) 27 July 2016 (27.07.2016)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference 200222-WOPCT	
International application No. PCT/GB2015/051312	International filing date (day/month/year) 05 May 2015 (05.05.2015)

1. The following indications appeared on record concerning:

☐ the applicant

☒ the inventor

☐ the agent

☐ the common representative

Name and Address BARLAAM, Bernard Christophe AstraZeneca R&D Alderley Alderley Park Macclesfield Cheshire SK10 4TG United Kingdom	State of Nationality	State of Residence
	Telephone No.	
	Facsimile No.	
	E-mail address	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person

☐ the name

☒ the address

☐ the nationality

☐ the residence

Name and Address BARLAAM, Bernard Christophe AstraZeneca, Darwin Building, Cambridge Science Park, Milton Road, Cambridge, CB4 0WG United Kingdom	State of Nationality	State of Residence
	Telephone No.	
	Facsimile No.	
	E-mail address ☐ Notifications by e-mail authorized	

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☐ the receiving Office

☒ the International Searching Authority

☐ the Authority(ies) specified for supplementary search

☐ the International Preliminary Examining Authority

☒ the designated Offices concerned

☐ the elected Offices concerned

☐ other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Safi Horiya
Facsimile No. +41 22 338 89 95	e-mail pt04.pct@wipo.int Telephone No. +41 22 338 74 04